Compare · GLP-1 agonist
Liraglutide vs VK2735
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| Liraglutide | VK2735 | |
|---|---|---|
| Evidence | 10/10 | 7/10 |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | A once-daily GLP-1 drug with large RCT support for glucose control, weight loss, and lower cardiovascular risk in high-risk type 2 diabetes. | VK2735 is an investigational dual GLP-1/GIP receptor agonist from Viking Therapeutics being studied for obesity and metabolic disease. Phase 2 data are promising but it is not approved anywhere, and long-term safety is unknown. |
| Full profile → | Full profile → |
Liraglutide
Liraglutide is one of the most thoroughly studied metabolic drugs of the last fifteen years, and it's the direct predecessor to semaglutide. Its two approved uses rest on large, repeated, double-blind randomized trials (carefully controlled studies where neither patients nor doctors know who got…
VK2735
VK2735 is an experimental obesity drug from a company called Viking Therapeutics. It's part of the incretin family (a group of gut-hormone-based drugs that turn down appetite) — the same broad family as semaglutide and tirzepatide. It has drawn a lot of buzz for two reasons: its early results in…